719 related articles for article (PubMed ID: 32652164)
1. Safety and efficacy of anti-il6-receptor tocilizumab use in severe and critical patients affected by coronavirus disease 2019: A comparative analysis.
Rossotti R; Travi G; Ughi N; Corradin M; Baiguera C; Fumagalli R; Bottiroli M; Mondino M; Merli M; Bellone A; Basile A; Ruggeri R; Colombo F; Moreno M; Pastori S; Perno CF; Tarsia P; Epis OM; Puoti M;
J Infect; 2020 Oct; 81(4):e11-e17. PubMed ID: 32652164
[TBL] [Abstract][Full Text] [Related]
2. Experience with tocilizumab in severe COVID-19 pneumonia after 80 days of follow-up: A retrospective cohort study.
Moreno-Pérez O; Andres M; Leon-Ramirez JM; Sánchez-Payá J; Rodríguez JC; Sánchez R; García-Sevila R; Boix V; Gil J; Merino E
J Autoimmun; 2020 Nov; 114():102523. PubMed ID: 32690352
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of tocilizumab in severe COVID-19 patients: a single-centre retrospective cohort study.
Campochiaro C; Della-Torre E; Cavalli G; De Luca G; Ripa M; Boffini N; Tomelleri A; Baldissera E; Rovere-Querini P; Ruggeri A; Monti G; De Cobelli F; Zangrillo A; Tresoldi M; Castagna A; Dagna L;
Eur J Intern Med; 2020 Jun; 76():43-49. PubMed ID: 32482597
[TBL] [Abstract][Full Text] [Related]
4. Effect of Tocilizumab vs Usual Care in Adults Hospitalized With COVID-19 and Moderate or Severe Pneumonia: A Randomized Clinical Trial.
Hermine O; Mariette X; Tharaux PL; Resche-Rigon M; Porcher R; Ravaud P;
JAMA Intern Med; 2021 Jan; 181(1):32-40. PubMed ID: 33080017
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of tocilizumab in patients with COVID-19 ARDS undergoing noninvasive ventilation.
Menzella F; Fontana M; Salvarani C; Massari M; Ruggiero P; Scelfo C; Barbieri C; Castagnetti C; Catellani C; Gibellini G; Falco F; Ghidoni G; Livrieri F; Montanari G; Casalini E; Piro R; Mancuso P; Ghidorsi L; Facciolongo N
Crit Care; 2020 Sep; 24(1):589. PubMed ID: 32993751
[TBL] [Abstract][Full Text] [Related]
6. Promising effects of tocilizumab in COVID-19: A non-controlled, prospective clinical trial.
Dastan F; Saffaei A; Haseli S; Marjani M; Moniri A; Abtahian Z; Abedini A; Kiani A; Seifi S; Jammati H; Hashemian SMR; Pourabdollah Toutkaboni M; Eslaminejad A; Heshmatnia J; Sadeghi M; Nadji SA; Dastan A; Baghaei P; Varahram M; Yousefian S; Salamzadeh J; Tabarsi P
Int Immunopharmacol; 2020 Nov; 88():106869. PubMed ID: 32889241
[TBL] [Abstract][Full Text] [Related]
7. Tocilizumab therapy reduced intensive care unit admissions and/or mortality in COVID-19 patients.
Klopfenstein T; Zayet S; Lohse A; Balblanc JC; Badie J; Royer PY; Toko L; Mezher C; Kadiane-Oussou NJ; Bossert M; Bozgan AM; Charpentier A; Roux MF; Contreras R; Mazurier I; Dussert P; Gendrin V; Conrozier T;
Med Mal Infect; 2020 Aug; 50(5):397-400. PubMed ID: 32387320
[TBL] [Abstract][Full Text] [Related]
8. Tocilizumab treatment in COVID-19: A single center experience.
Luo P; Liu Y; Qiu L; Liu X; Liu D; Li J
J Med Virol; 2020 Jul; 92(7):814-818. PubMed ID: 32253759
[TBL] [Abstract][Full Text] [Related]
9. Low-dose subcutaneous tocilizumab to prevent disease progression in patients with moderate COVID-19 pneumonia and hyperinflammation.
Potere N; Di Nisio M; Rizzo G; La Vella M; Polilli E; Agostinone A; Spacone A; Di Carlo S; Costantini A; Abbate A; Porreca E; Parruti G
Int J Infect Dis; 2020 Nov; 100():421-424. PubMed ID: 32768701
[TBL] [Abstract][Full Text] [Related]
10. Impact of low dose tocilizumab on mortality rate in patients with COVID-19 related pneumonia.
Capra R; De Rossi N; Mattioli F; Romanelli G; Scarpazza C; Sormani MP; Cossi S
Eur J Intern Med; 2020 Jun; 76():31-35. PubMed ID: 32405160
[TBL] [Abstract][Full Text] [Related]
11. Interleukin-6 receptor blocking with intravenous tocilizumab in COVID-19 severe acute respiratory distress syndrome: A retrospective case-control survival analysis of 128 patients.
Canziani LM; Trovati S; Brunetta E; Testa A; De Santis M; Bombardieri E; Guidelli G; Albano G; Folci M; Squadroni M; Beretta GD; Ciccarelli M; Castoldi M; Lleo A; Aghemo A; Vernile L; Malesci A; Omodei P; Angelini C; Badalamenti S; Cecconi M; Cremonesi A; Selmi C;
J Autoimmun; 2020 Nov; 114():102511. PubMed ID: 32713677
[TBL] [Abstract][Full Text] [Related]
12. Tocilizumab for the treatment of severe COVID-19 pneumonia with hyperinflammatory syndrome and acute respiratory failure: A single center study of 100 patients in Brescia, Italy.
Toniati P; Piva S; Cattalini M; Garrafa E; Regola F; Castelli F; Franceschini F; Airò P; Bazzani C; Beindorf EA; Berlendis M; Bezzi M; Bossini N; Castellano M; Cattaneo S; Cavazzana I; Contessi GB; Crippa M; Delbarba A; De Peri E; Faletti A; Filippini M; Filippini M; Frassi M; Gaggiotti M; Gorla R; Lanspa M; Lorenzotti S; Marino R; Maroldi R; Metra M; Matteelli A; Modina D; Moioli G; Montani G; Muiesan ML; Odolini S; Peli E; Pesenti S; Pezzoli MC; Pirola I; Pozzi A; Proto A; Rasulo FA; Renisi G; Ricci C; Rizzoni D; Romanelli G; Rossi M; Salvetti M; Scolari F; Signorini L; Taglietti M; Tomasoni G; Tomasoni LR; Turla F; Valsecchi A; Zani D; Zuccalà F; Zunica F; Focà E; Andreoli L; Latronico N
Autoimmun Rev; 2020 Jul; 19(7):102568. PubMed ID: 32376398
[TBL] [Abstract][Full Text] [Related]
13. Appropriate use of tocilizumab in COVID-19 infection.
Keske Ş; Tekin S; Sait B; İrkören P; Kapmaz M; Çimen C; Uğur S; Çelebi İ; Bakır VO; Palaoğlu E; Şentürk E; Çağlayan B; Çakar N; Tabak L; Ergönül Ö
Int J Infect Dis; 2020 Oct; 99():338-343. PubMed ID: 32726724
[TBL] [Abstract][Full Text] [Related]
14. Biomarker variation in patients successfully treated with tocilizumab for severe coronavirus disease 2019 (COVID-19): results of a multidisciplinary collaboration.
Conrozier T; Lohse A; Balblanc JC; Dussert P; Royer PY; Bossert M; Bozgan AM; Gendrin V; Charpentier A; Toko L; Badie J; Mezher C; Roux MF; Kadiane-Oussou NJ; Contreras R; Kessler J; Mazurier I; Klopfenstein T; Zayet S
Clin Exp Rheumatol; 2020; 38(4):742-747. PubMed ID: 32573419
[TBL] [Abstract][Full Text] [Related]
15. Tocilizumab for severe COVID-19 pneumonia: Case series of 5 Australian patients.
West TA; Malik S; Nalpantidis A; Tran T; Cannon C; Bhonagiri D; Chan K; Cheong E; Wan Sai Cheong J; Cheung W; Choudhury F; Ernest D; Farah CS; Fernando S; Kanapathipillai R; Kol M; Murfin B; Naqvi H; Shah A; Wagh A; Ojaimi S; Frankum B; Riminton S; Keat K
Int J Rheum Dis; 2020 Aug; 23(8):1030-1039. PubMed ID: 32881350
[TBL] [Abstract][Full Text] [Related]
16. Safety and efficacy of tocilizumab in the treatment of severe acute respiratory syndrome coronavirus-2 pneumonia: A retrospective cohort study.
Patel A; Shah K; Dharsandiya M; Patel K; Patel T; Patel M; Reljic T; Kumar A
Indian J Med Microbiol; 2020; 38(1):117-123. PubMed ID: 32719218
[TBL] [Abstract][Full Text] [Related]
17. Impact of tocilizumab on mortality and/or invasive mechanical ventilation requirement in a cohort of 206 COVID-19 patients.
Klopfenstein T; Zayet S; Lohse A; Selles P; Zahra H; Kadiane-Oussou NJ; Toko L; Royer PY; Balblanc JC; Gendrin V; Conrozier T;
Int J Infect Dis; 2020 Oct; 99():491-495. PubMed ID: 32798660
[TBL] [Abstract][Full Text] [Related]
18. Negative impact of hyperglycaemia on tocilizumab therapy in Covid-19 patients.
Marfella R; Paolisso P; Sardu C; Bergamaschi L; D'Angelo EC; Barbieri M; Rizzo MR; Messina V; Maggi P; Coppola N; Pizzi C; Biffi M; Viale P; Galié N; Paolisso G
Diabetes Metab; 2020 Oct; 46(5):403-405. PubMed ID: 32447102
[TBL] [Abstract][Full Text] [Related]
19. Clinical characteristics and predictors of survival in adults with coronavirus disease 2019 receiving tocilizumab.
Morrison AR; Johnson JM; Griebe KM; Jones MC; Stine JJ; Hencken LN; To L; Bianchini ML; Vahia AT; Swiderek J; Ramesh MS; Peters MA; Smith ZR
J Autoimmun; 2020 Nov; 114():102512. PubMed ID: 32646770
[TBL] [Abstract][Full Text] [Related]
20. Tocilizumab for patients with COVID-19 pneumonia. The single-arm TOCIVID-19 prospective trial.
Perrone F; Piccirillo MC; Ascierto PA; Salvarani C; Parrella R; Marata AM; Popoli P; Ferraris L; Marrocco-Trischitta MM; Ripamonti D; Binda F; Bonfanti P; Squillace N; Castelli F; Muiesan ML; Lichtner M; Calzetti C; Salerno ND; Atripaldi L; Cascella M; Costantini M; Dolci G; Facciolongo NC; Fraganza F; Massari M; Montesarchio V; Mussini C; Negri EA; Botti G; Cardone C; Gargiulo P; Gravina A; Schettino C; Arenare L; Chiodini P; Gallo C;
J Transl Med; 2020 Oct; 18(1):405. PubMed ID: 33087150
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
